Pharmaceuticals
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
* Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. * The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in Lexington, Kentucky. * This partnership addresse...
2026-09-30 21:54
1196
Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC
First clinical program built on Phrontline's DLP1 branched dual-payload linker platform HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), today announced that the f...
2026-09-30 21:53
1242
Yuyu Pharma Brings Ari's Purrfect to Amazon Accelerate 2026
Korean pharmaceutical company explores Amazon AI and seller tools to grow its U.S. feline-health brand SEOUL, South Korea, Sept. 30, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma (KRX: 000220), attended Amazon Accelerate 2026 in Seattle from September 22 to 24 to explore how Amazon'...
2026-09-30 21:00
686
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical
2026-09-30 20:00
755
EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity
HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announced that its Phase 1b randomized, double-blind, placebo-controlled study of ecnoglutide, the worl...
2026-09-30 19:00
1311
Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma
SEONGNAM, South Korea, Sept. 30, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the Orpha...
2026-09-30 17:33
699
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become th...
2026-09-30 13:57
917
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
* Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. * With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province's leadership p...
2026-09-30 03:28
2321
Yuyu Teijin Medicare Uses Drones to Deliver Medical Supplies to Patients on Korea's Remote Islands
SEOUL, South Korea, Sept. 29, 2026 /PRNewswire/ -- Yuyu Teijin Medicare, a home healthcare joint venture between Yuyu Pharma of Korea and Teijin Pharma of Japan, has completed a pilot delivery of medical supplies by drone to a ventilator patient living on a remote Korean island. In the test, a d...
2026-09-29 21:00
1676
iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. CHENGDU, China, Sept. 29, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemical...
2026-09-29 13:41
1687
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
* HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing * Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharm...
2026-09-29 13:12
1749
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabol...
2026-09-28 18:30
2046
111, Inc. Announces Establishment of the Special Committee
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three independent directors, Mr. Jian Sun, who is the chairma...
2026-09-28 16:30
2723
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
TOKYO and BOSTON, Sept. 28, 2026 /PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan Agency f...
2026-09-28 14:00
1995
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific...
2026-09-28 10:05
3346
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabo...
2026-09-28 08:00
2089
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms,FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate --- with median PFS and OS not yet reached (12-mo...
2026-09-27 11:16
2445
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in a popula...
2026-09-27 11:03
6894
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch cli...
2026-09-25 20:00
9492
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
* This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's AI and robotics-driven drug discovery platform and its transition to a clinical-stage organization. * Preclinical data demonstrate sub-nanomol...
2026-09-25 08:30
3785
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
DOKU Names Himelda Renuat CEO as Ant International's Antom Deepens Strategic Investment in Indonesia's Payments Leader
[Picked up by 274 media titles]
2026-09-24 10:00
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13918
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12625
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11693
